In this interview, Deepak Bhatt, MD, MPH, FACC and Alison L. Bailey, MD FACC, discuss the Top Interventional Cardiology Takeaways from 2025 including DanGer Shock trial, revascularization in STEMI, ...

In this interview, Allen J. Taylor, MD, FACC and Alison L. Bailey, MD FACC, discuss the Top Clinical Cardiology Takeaways from 2025 including trials SCOT-HEART 2, ALONE-AF, Launch-HTN, and more.

During ACC's 75th Anniversary, we're celebrating our legacy and preparing to shape the next 75 years. Help us invest in the future of cardiology with a gift to the ACC Foundation. Gifts support a ...

We are a young, vibrant section dedicated to adding value to Section members interested in Innovation across the cardiovascular spectrum. Our section is member-driven and focused on all aspects of ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

Semaglutide, the popular anti-obesity medication originally developed to treat diabetes, continues to show cardiovascular benefits beyond weight loss, including reducing risk of death, reducing ...

Until about 15 years ago, most cardiologists were found in private practices, where the physicians – usually in groups – owned the practice and had privileges for hospital-based services at one or ...

The ACC has issued guidance for the diagnosis and management of acute myocarditis in adult patients, delivering a streamlined decision-making framework that reflects recent advancements in clinical ...

A newly released ACC Expert Consensus Decision Pathway (ECDP) focused on the clinical assessment, management and trajectory of patients hospitalized with heart failure (HF) includes revisions to the ...

"Who I am NOT has captured a lot of people's attention. So, who am I? I am Cathie Biga, a leader, health care administrator, nurse, executive, mom, wife, nana and I still think of myself as a ...

The U.S. Food and Drug Administration (FDA) announced on April 15 that Abbott/Thoratec Corp. is recalling the Heartmate II and Heartmate 3 Left Ventricular Assist System (LVAS) due to long-term ...

Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career! For a filtered job search and to sign up for customized job alerts and ...